Papers/PMID:30156145
The Effects of Curcumin on Glycemic Control and Lipid Profiles Among Patients with Metabolic Syndrome and Related Disorders: A Systematic Review and Metaanalysis of Randomized Controlled Trials.
Current pharmaceutical design2018The record
3 findings · 1 compound · 3 endpoints · 1 null
What it reported
How to read these marksWhat moved
2 findings
curcumin — decreases total cholesterol (TC)
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×4“In addition, curcumin supplementation was significantly associated with triglyceride (SMD -1.21; 95 % CI, -1.78, -0.65; P<0.001) and total cholesterol reduction (SMD -0.73; 95 % CI, -1.32, -0.13; P= 0.01).”
Quoted verbatim from The Effects of Curcumin on Glycemic Control and Lipid Profiles Among Patients with Metabolic Syndrome and Related Disorders: A Systematic Review and Metaanalysis of Randomized Controlled Trials.. - Study
- meta-analysis
- Population
- patients with metabolic syndrome (MetS) and related disorders
Effect -0.73 standardised mean difference, 95% CI -1.32 to -0.13
The Effects of Curcumin on Glycemic Control and Lipid Profiles Among Patients with Metabolic Syndrome and Related Disorders: A Systematic Review and Metaanalysis of Randomized Controlled Trials.2018PMID:30156145Permalink
curcumin — decreases triglycerides
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×4“In addition, curcumin supplementation was significantly associated with triglyceride (SMD -1.21; 95 % CI, -1.78, -0.65; P<0.001) and total cholesterol reduction (SMD -0.73; 95 % CI, -1.32, -0.13; P= 0.01).”
Quoted verbatim from The Effects of Curcumin on Glycemic Control and Lipid Profiles Among Patients with Metabolic Syndrome and Related Disorders: A Systematic Review and Metaanalysis of Randomized Controlled Trials.. - Study
- meta-analysis
- Population
- patients with metabolic syndrome (MetS) and related disorders
Effect -1.21 standardised mean difference, 95% CI -1.78 to -0.65
The Effects of Curcumin on Glycemic Control and Lipid Profiles Among Patients with Metabolic Syndrome and Related Disorders: A Systematic Review and Metaanalysis of Randomized Controlled Trials.2018PMID:30156145Permalink
What did not
1 finding
curcumin — no detected effect on HDL cholesterol
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull resultreplicated ×8“We found no significant effect of curcumin supplementation on LDL- (SMD -0.52; 95% CI, -1.14, 0.11; P=0.10) and HDL-cholesterol levels (SMD 0.28; 95% CI, -0.22, 0.77; P=0.27).”
Quoted verbatim from The Effects of Curcumin on Glycemic Control and Lipid Profiles Among Patients with Metabolic Syndrome and Related Disorders: A Systematic Review and Metaanalysis of Randomized Controlled Trials.. - Study
- meta-analysis
- Population
- patients with metabolic syndrome (MetS) and related disorders
Effect 0.28 standardised mean difference, 95% CI -0.22 to 0.77
The Effects of Curcumin on Glycemic Control and Lipid Profiles Among Patients with Metabolic Syndrome and Related Disorders: A Systematic Review and Metaanalysis of Randomized Controlled Trials.2018PMID:30156145Permalink